We are Sorry, This Page doesn't Exist

On CNBC's "Fast Money Halftime Report," Jon Najarian suggested Amicus Therapeutics, Inc. (NASDAQ: FOLD) is a buy. read more.....»»

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and........»»

On Tuesday, Amicus Therapeutics (NASDAQ: FOLD) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are pre.....»»

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We .....»»

Dividend Channel.....»»

Stock Options Channel.....»»

2018’s fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip.....»»

Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among.....»»

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2019 Results - Earnings Call Transcript.....»»

Stock Options Channel.....»»

Stock Options Channel.....»»

Hedge funds are known to underperform the bull markets but that’s not because they are bad at investing. Truth be told, most hedge fund m.....»»

Stock Options Channel.....»»

Amicus Therapeutics (FOLD) Presents Additional Data from Phase 1/2 Study of AT-GAA - Slideshow.....»»

Dividend Channel.....»»

Zacks.....»»

Stock Options Channel.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO) Allakos Inc (NASDAQ: ALLK) Cytokinetics, Inc. (NASDAQ:.....»»

Stock Options Channel.....»»

Stock Options Channel.....»»